Pharvaris N.V. (PHVS) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Biotechnology) last closed at $31.19. The rating moved from Strong Oversold to Oversold on September 25, 2026.

• Public ratingOversold (as of October 3, 2026)
• Last close$31.19
• Last changeMoved from Strong Oversold to Oversold on September 25, 2026
• SectorHealthcare
• IndustryBiotechnology

See all oversold Healthcare stocks →

AI analysis

Pharvaris N.V. is a clinical-stage biotech whose market value is highly dependent on binary clinical and regulatory events and on access to capital. Current macro and sector conditions show a cautious bias that can depress small-cap healthcare names, while selective investor interest in late-stage biologics provides some offset via potential funding and M&A optionality. Key drivers over the coming weeks are clinical readouts, partnership/financing announcements, and any signs of payer or regulatory pressure. Given thin liquidity and high execution risk, expect elevated volatility and a wide range of plausible outcomes absent clear positive catalysts.

Key factors

• Clinical-stage biotech profile with valuation sensitive to binary trial/regulatory outcomes
• Sector-wide risk-off tone reducing appetite for smaller healthcare names and new issues
• Policy pressure on drug pricing (Medicare negotiations) could affect pricing power for specialty therapies
• Positive subsector dynamics for late-stage biologics and selective insider/specialist buying that can support funding and M&A optionality
• Limited public/social sentiment and thin trading volumes increase volatility and widen bid/ask spreads
• Near-term catalysts likely tied to clinical readouts, regulatory milestones, partnerships or financing activity

Risks

• Clinical or regulatory setbacks for lead programs that would materially reduce valuation
• Need to raise capital in an unfavorable market, causing dilution and downward pressure on share price
• Adverse shifts in payer policy or pricing (Medicare/IRA-related actions) reducing future revenue potential
• Broader market risk-off episodes, geopolitical headlines or declines in biotech risk appetite
• Low liquidity and high idiosyncratic volatility making short-term price moves large and unpredictable
• Competition from larger incumbents or adjacent modality innovators impacting market share for any approved products

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.